|Bid||63.02 x 800|
|Ask||63.55 x 900|
|Day's Range||62.84 - 64.20|
|52 Week Range||60.89 - 70.50|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||30.10|
|Earnings Date||Feb 03, 2020|
|Forward Dividend & Yield||2.52 (3.97%)|
|Ex-Dividend Date||Dec 11, 2019|
|1y Target Est||76.39|
(Bloomberg Opinion) -- We aren’t completely unprepared for the Wuhan coronavirus now spreading around the world. Just ask the people who work in Tyvek suits and respirators, such as epidemiologist Timothy Sheahan of the University of North Carolina.He has been studying coronaviruses since 2003, shortly after a similar virus triggered the SARS outbreak, which also started in China and spread to North America. In the end, it killed fewer than 800 people but raised legitimate fears about a global pandemic.Now there’s a drug called remdesivir which Sheahan and his colleagues at UNC, in collaboration with Gilead Sciences, have been testing in a level 3 containment facility for its ability to fight a whole range of coronaviruses — so named for their spiky shape, which resembles a crown.Sheahan said their drug targets an enzyme that different kinds of coronaviruses need to replicate themselves. They’ve tested the drug in mice infected with the SARS virus, as well as MERS — Middle East respiratory syndrome — another coronavirus that has killed 851 people since it broke out in 2012. They published the MERS results this month in Nature Communications.Clinical trials in these cases usually test drugs’ effectiveness as compared with other therapies, rather than against a placebo. Such comparative testing is still being done with Ebola — which is currently infecting people in the Democratic Republic of Congo. Though Ebola is not a coronavirus, it is, like SARS and the new infection, a so-called RNA virus, and so doctors tested remdesivir against other Ebola therapies. It didn’t perform as well as a different kind of therapy, but it did prove reasonably safe.Sheahan says his work is part of a program on emerging infectious diseases, funded by the National Institutes of Health. How did the NIH have the foresight to fund research on coronavirus cures, when there hasn’t been a case of SARS since 2004 and there’s little fear that MERS will spread in the United States?Experts say they knew it was likely that another dangerous coronavirus would emerge in China. That’s because SARS — which stands for Severe Acute Respiratory Syndrome — was eventually found to come from wild bats, and bats carry a whole cauldron of different strains of SARS-like coronaviruses. Bats are considered a “reservoir” for coronaviruses because they can carry them without getting sick.The story of SARS is well-told in David Quammen’s book “Spillover: Animal Infections and the Next Human Pandemic.” A determined group of investigators swabbing thousands of animals eventually found that people in China got the disease from eating small mammals called civets. The civets were likely infected by bats in a so-called wet market, where a vast array of wild and domestic species are stored in stacked up cages and exposed to one another’s wastes and germs before being butchered. The Chinese killed thousands of civets in an attempt to eradicate the virus, before they realized it was going to remain indefinitely in the bodies of wild bats — which some people there still consider a delicacy. The new disease appears to have emerged from a seafood market that also sold live mammals and birds, though the original animal host has yet to be identified.SARS was, ultimately, the story of a bullet dodged. According to Quammen’s account, the factor that worked in humanity’s favor was the pattern of contagion. While influenza tends to spread most readily when people first get sick, before the peak of their symptoms, SARS becomes most transmissible during or after symptoms hit their peak. It’s a lot easier to quarantine people who are or have been sick than those who have yet to notice symptoms.If the scientists working in level 3 containment facilities to develop cures can be thought of as the “special ops” part of the effort to protect the public, there’s also important work being done by the infantry: making sure hospitals worldwide are using the best standards for sanitation and protection of healthcare workers. All hospitals should be equipped to diagnose the disease, says virologist David Sanders of Purdue University, and regional centers should be set up as needed to treat patients.One chilling aspect of the SARS epidemic was the speed with which health care workers got sick and died. It happened in Asia, and then in Toronto, where the disease first appeared in North America. Investigations of the Toronto hospitals showed lapses, in some cases simply because health care workers had no idea what they were dealing with. SARS wasn’t a global pandemic, but it was still a tragic story as dozens of doctors and nurses, many of them young, were struck down in the line of duty.Experts say this Wuhan virus is unlikely to turn into a global pandemic — and whether it becomes as tragic as SARS depends on cutting-edge science and simple sanitation. The fact that our world is full of potentially deadly viruses is scary, but we are not helpless in the face of them.To contact the author of this story: Faye Flam at email@example.comTo contact the editor responsible for this story: Sarah Green Carmichael at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Faye Flam is a Bloomberg Opinion columnist. She has written for the Economist, the New York Times, the Washington Post, Psychology Today, Science and other publications. She has a degree in geophysics from the California Institute of Technology.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
At least three Bay Area companies say they could jumpstart programs to find treatments or vaccines for the respiratory infection that has swept part of China and crept into two people in the United States.
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
The S&P 500 ended slightly higher and the Nasdaq eked out a record closing high on Thursday, helped by a jump in Netflix, while news about the coronavirus outbreak spreading from China and mixed earnings results kept a lid on the market. The S&P and the Nasdaq had both been trading down before news late in the session that Gilead Sciences Inc was assessing its experimental Ebola drug as a possible treatment for the virus.
Wall Street struggled for direction on Thursday as investors digested mixed earnings and developing news about the coronavirus outbreak emanating from China. Health officials in China put millions of people on lockdown in efforts to contain a coronavirus outbreak that has so far claimed 18 lives, but the World Health Organization (WHO) announced it was "a bit too early" to declare the virus a global health emergency. Additionally, a spate of earnings reports, while beating Street estimates in many cases, have failed to impress investors.
Gilead Sciences Inc said on Thursday it was assessing whether its experimental Ebola treatment could be used to treat coronavirus infection. "Gilead is in active discussions with researchers and clinicians in the United States and China regarding the ongoing Wuhan coronavirus outbreak and the potential use of remdesivir as an investigational treatment," a company spokesman said in an emailed statement.
There was one value strategy that wasn’t a disaster in 2019, and it now likes commodity producers over techs.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s fourth quarter and full year 2019 financial results and will provide a business update.
Gilead Sciences' next chapter is still murky, an analyst said Friday, noting a dearth of expected takeovers among biotech stocks during the annual J.P. Morgan Healthcare Conference.
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor
Cell therapy's initial applications have been in cancer. This deal could rev up its use against a wide range of diseases where the immune system goes wild and attacks the body.
Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, announced today that it has raised $25 million in a Series A investment from Vida Ventures and Westlake Village BioPartners, both of which were founding investors, as well as Gilead Sciences (NASDAQ: GILD). Proceeds from the financing will be used to advance Kyverna's therapeutic strategy which combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease. Dominic Borie, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO). Jeffrey Greve, Ph.D., will continue to serve as Kyverna's Chief Scientific Officer (CSO). Prior to Kyverna, Dr. Greve founded and served as CSO of Delinia, an autoimmune disease company acquired by Celgene in 2017.